Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia.

It has been shown that the novel synthetic triterpenoid CDDO inhibits proliferation and induces differentiation and apoptosis in myeloid leukemia cells. In the current study the effects of the C-28 methyl ester of CDDO, CDDO-Me, were analyzed on cell growth and apoptosis of leukemic cell lines and primary acute myelogenous leukemia (AML). CDDO-Me decreased the viability of leukemic cell lines, including multidrug resistant (MDR)-1-overexpressing, p53(null) HL-60-Dox and of primary AML cells, and it was 3- to 5-fold more active than CDDO. CDDO-Me induced a loss of mitochondrial membrane potential, induction of caspase-3 cleavage, increase in annexin V binding and DNA fragmentation, suggesting the induction of apoptosis. CDDO-Me induced pro-apoptotic Bax protein that preceded caspase activation. Furthermore, CDDO-Me inhibited the activation of ERK1/2, as determined by the inhibition of mitochondrial ERK1/2 phosphorylation, and it blocked Bcl-2 phosphorylation, rendering Bcl-2 less anti-apoptotic. CDDO-Me induced granulo-monocytic differentiation in HL-60 cells and monocytic differentiation in primary cells. Of significance, colony formation of AML progenitors was significantly inhibited in a dose-dependent fashion, whereas normal CD34(+) progenitor cells were less affected. Combinations with ATRA or the RXR-specific ligand LG100268 enhanced the effects of CDDO-Me on cell viability and terminal differentiation of myeloid leukemic cell lines. In conclusion, CDDO-Me is an MDR-1- and a p53-independent compound that exerts strong antiproliferative, apoptotic, and differentiating effects in myeloid leukemic cell lines and in primary AML samples when given in submicromolar concentrations. Differential effects of CDDO-Me on leukemic and normal progenitor cells suggest that CDDO-Me has potential as a novel compound in the treatment of hematologic malignancies.

[1]  R Berger,et al.  NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). , 1991, Blood.

[2]  M. Sporn.  Chemoprevention of cancer. , 1993, Lancet.

[3]  P F Thall,et al.  Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. , 1999, Blood.

[4]  W. May,et al.  Survival function of ERK1/2 as IL-3-activated, staurosporine-resistant Bcl2 kinases. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[5]  M. Konopleva,et al.  Apoptosis. Molecules and mechanisms. , 1999, Advances in experimental medicine and biology.

[6]  M. Sporn,et al.  A novel synthetic oleanane triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, with potent differentiating, antiproliferative, and anti-inflammatory activity. , 1999, Cancer research.

[7]  B. Dörken,et al.  Expression of the bcl‐2 gene family in normal and malignant breast tissue: Low bax‐α expression in tumor cells correlates with resistance towards apoptosis , 1995, International journal of cancer.

[8]  John Calvin Reed.  Double identity for proteins of the Bcl-2 family , 1997, Nature.

[9]  M. Lishner,et al.  Interaction between retinoic acid and cytosine arabinoside affecting the blast cells of acute myeloblastic leukemia. , 1989, Leukemia.

[10]  D. Cortez,et al.  The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells , 1997, Oncogene.

[11]  J. Hahn,et al.  Constitutive activation of extracellular signal-regulated kinase in human acute leukemias: combined role of activation of MEK, hyperexpression of extracellular signal-regulated kinase, and downregulation of a phosphatase, PAC1. , 1999, Blood.

[12]  Guido Kroemer,et al.  Mitochondria and programmed cell death: back to the future , 1996, FEBS letters.

[13]  E. Estey,et al.  Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  R. Gascoyne,et al.  Immunohistochemical analysis of Mcl-1 and Bcl-2 proteins in normal and neoplastic lymph nodes. , 1994, The American journal of pathology.

[15]  G. Gao,et al.  N‐terminal cleavage of Bax by calpain generates a potent proapoptotic 18‐kDa fragment that promotes Bcl‐2‐independent cytochrome C release and apoptotic cell death , 2000, Journal of cellular biochemistry.

[16]  The Risk of Residual Molecular and Cytogenetic Disease in Patients With Philadelphia-Chromosome Positive First Chronic Phase Chronic Myelogenous Leukemia Is Reduced After Transplantation of Allogeneic Peripheral Blood Stem Cells Compared With Bone Marrow , 1999 .

[17]  D. Niederwieser,et al.  Treatment of relapsed and refractory acute myelogenous leukaemia with aclacinomycin A (ACA) and etoposide (VP-16). , 1994, Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis.

[18]  W. May,et al.  Bcl-2 Phosphorylation Required for Anti-apoptosis Function* , 1997, The Journal of Biological Chemistry.

[19]  Andreeff,et al.  Apoptosis regulating proteins as targets of therapy for haematological malignancies. , 1999, Expert opinion on investigational drugs.

[20]  J. Mccormick.  EMIGRATION AND MENTAL SUBNORMALITY IN NORTHERN IRELAND , 1974 .

[21]  W. May,et al.  A Functional Role for Mitochondrial Protein Kinase Cα in Bcl2 Phosphorylation and Suppression of Apoptosis* , 1998, The Journal of Biological Chemistry.

[22]  M. Melamed,et al.  Discrimination of human leukemia subtypes by flow cytometric analysis of cellular DNA and RNA. , 1980, Blood.

[23]  E. Estey,et al.  Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  M. Minden,et al.  Regulation by retinoic acid and hydrocortisone of the anthracycline sensitivity of blast cells of acute myeloblastic leukemia. , 1994, Leukemia.

[25]  K. Bhalla,et al.  Overexpression of Bcl-2 or Bcl-xL inhibits Ara-C-induced CPP32/Yama protease activity and apoptosis of human acute myelogenous leukemia HL-60 cells. , 1996, Cancer research.

[26]  H. Nishino,et al.  Inhibition of the tumor-promoting action of 12-O-tetradecanoylphorbol-13-acetate by some oleanane-type triterpenoid compounds. , 1988, Cancer research.

[27]  S. Korsmeyer,et al.  Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death , 1993, Cell.

[28]  M. Andreeff,et al.  Retinoic Acid-induced Expression of CD38 Antigen in Myeloid Cells Is Mediated through Retinoic Acid Receptor-α , 1994 .

[29]  L. Neckers,et al.  Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. , 1996, Cancer research.

[30]  J. Reed,et al.  High levels of p26BCL-2 oncoprotein retard taxol-induced apoptosis in human pre-B leukemia cells. , 1994, Leukemia.

[31]  C. Croce,et al.  Bcl2 is the guardian of microtubule integrity. , 1997, Cancer research.

[32]  K. Kinzler,et al.  Role of BAX in the apoptotic response to anticancer agents. , 2000, Science.

[33]  P. G. Tyler,et al.  Interleukin-3 and bryostatin-1 mediate hyperphosphorylation of BCL2 alpha in association with suppression of apoptosis. , 1994, The Journal of biological chemistry.

[34]  E. Cheng,et al.  Conversion of Bcl-2 to a Bax-like death effector by caspases. , 1997, Science.

[35]  John Calvin Reed,et al.  Bcl-2 Targets the Protein Kinase Raf-1 to Mitochondria , 1996, Cell.

[36]  T. Tsuruo,et al.  Requirement of the Caspase-3/CPP32 Protease Cascade for Apoptotic Death following Cytokine Deprivation in Hematopoietic Cells* , 1997, The Journal of Biological Chemistry.

[37]  S. Korsmeyer,et al.  Molecular thanatopsis: a discourse on the BCL2 family and cell death. , 1996, Blood.

[38]  M. Sporn,et al.  Synthetic oleanane and ursane triterpenoids with modified rings A and C: a series of highly active inhibitors of nitric oxide production in mouse macrophages. , 2000, Journal of medicinal chemistry.

[39]  G. Kroemer,et al.  Chloromethyl-X-Rosamine is an aldehyde-fixable potential-sensitive fluorochrome for the detection of early apoptosis. , 1996, Cytometry.

[40]  M. Sporn,et al.  A synthetic triterpenoid, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), is a ligand for the peroxisome proliferator-activated receptor gamma. , 2000, Molecular endocrinology.

[41]  J C Reed,et al.  Bax directly induces release of cytochrome c from isolated mitochondria. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[42]  Z. Oltvai,et al.  Interleukin-3 Induces the Phosphorylation of a Distinct Fraction of Bcl-2* , 1999, The Journal of Biological Chemistry.

[43]  E. Estey,et al.  Effect of interleukin-1 beta converting enzyme inhibitor on acute myelogenous leukemia progenitor proliferation. , 1995, Blood.

[44]  S. Zhao,et al.  Cell-surface exposure of phosphatidylserine correlates with the stage of fludarabine-induced apoptosis in chronic lymphocytic leukemia and expression of apoptosis-regulating genes. , 2000, Cytometry.

[45]  S. Korsmeyer,et al.  Bax suppresses tumorigenesis and stimulates apoptosis in vivo , 1997, Nature.

[46]  M. Center,et al.  Mechanisms of multidrug resistance in HL60 cells: evidence that a surface membrane protein distinct from P-glycoprotein contributes to reduced cellular accumulation of drug. , 1988, Cancer research.

[47]  C. Rudin,et al.  Expression of bcl-xL can confer a multidrug resistance phenotype. , 1995, Blood.

[48]  John Calvin Reed,et al.  Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid , 1999, Leukemia.

[49]  C Haanen,et al.  A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. , 1995, Journal of immunological methods.

[50]  Y. Hsu,et al.  Cytosol-to-membrane redistribution of Bax and Bcl-X(L) during apoptosis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[51]  S. Korsmeyer.  Bcl-2 initiates a new category of oncogenes: regulators of cell death. , 1992, Blood.

[52]  P. Bernardi,et al.  Interactions of Cyclophilin with the Mitochondrial Inner Membrane and Regulation of the Permeability Transition Pore, a Cyclosporin A-sensitive Channel (*) , 1996, The Journal of Biological Chemistry.

[53]  C. Croce,et al.  Inactivation of Bcl-2 by phosphorylation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[54]  Z. Estrov,et al.  BAX and PKCα Modulate the Prognostic Impact of BCL2 Expression in Acute Myelogenous Leukemia , 2000 .

[55]  S. Orrenius,et al.  CPP32/Apopain Is a Key Interleukin 1 Converting Enzyme-like Protease Involved in Fas-mediated Apoptosis (*) , 1996, The Journal of Biological Chemistry.

[56]  D. Andrews,et al.  Bcl‐2 mutants with restricted subcellular location reveal spatially distinct pathways for apoptosis in different cell types. , 1996, The EMBO journal.

[57]  M. Sporn,et al.  The novel triterpenoid 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid induces apoptosis of human myeloid leukemia cells by a caspase-8-dependent mechanism. , 2000, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[58]  John Calvin Reed,et al.  Immunohistochemical analysis of in vivo patterns of Bcl-X expression. , 1994, Cancer research.

[59]  S. Grant,et al.  Induction of apoptosis and differentiation by fludarabine in human leukemia cells (U937): interactions with the macrocyclic lactone bryostatin 1 , 1999, Leukemia.

[60]  C. Croce,et al.  Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. , 1996, Cancer research.

[61]  J. Till,et al.  COLONY ASSAY FOR PROLIFERATIVE BLAST CELLS CIRCULATING IN MYELOBLASTIC LEUKÆMIA , 1977, The Lancet.

[62]  Najman,et al.  NB 4 , a Maturation Inducible Cell Line With t ( 15 ; 17 ) Marker Isolated From a Human Acute Promyelocytic Leukemia ( M 3 ) , 2022 .

[63]  M. Sporn,et al.  The novel triterpenoid CDDO induces apoptosis and differentiation of human osteosarcoma cells by a caspase-8 dependent mechanism. , 2001, Molecular pharmacology.

[64]  John Calvin Reed,et al.  Granzyme Release and Caspase Activation in Activated Human T-Lymphocytes* , 1998, The Journal of Biological Chemistry.

[65]  Y-M Zhu,et al.  Down‐regulation of bcl‐2 in AML blasts by all‐trans retinoic acid and its relationship to CD34 antigen expression , 1996, British journal of haematology.

[66]  Y. Lou,et al.  Inhibition of skin tumorigenesis by rosemary and its constituents carnosol and ursolic acid. , 1994, Cancer research.

[67]  H. Kantarjian,et al.  Acute myeloid leukemia , 2018, Methods in Molecular Biology.